摘要 |
The present invention relates to a novel indol derivative according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables R<SUP>1, R</SUP><SUP>2</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, p, a<SUP>1</SUP>-a<SUP>2</SUP>a<SUP>3</SUP>-a<SUP>4</SUP>, Z<SUP>1</SUP>-Z<SUP>2</SUP>, X and Y are defined as in claim 1 . Said derivative exhibit a binding affinity towards dopamine receptors, in particular towards dopamine D<SUB>2</SUB>, D<SUB>3 </SUB>and D<SUB>4 </SUB>receptors, with selective serotonin reuptake inhibition properties and acting as 5-HT<SUB>1A </SUB>agonists or partial agonists. The invention also relates to pharmaceutical compositions comprising the compounds according to the invention, the use thereof for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic disorders, most in particular schizophrenia and processes for their production.
|